Phase 1 study: New medicine extends terminally-ill cancer patients’ lives

A promising cancer drug that targets only cancer cells has been developed by researchers from the Norwegian University of Science and Technology (NTNU) and a university spin-off company, APIM Therapeutics.

Leave A Comment

Your email address will not be published. Required fields are marked *